GROWTH HORMONE AND GNRH AGONIST IN ADOLESCENTS WITH ACQUIRED HYPOTHYROIDISM

生长激素和 GNRH 激动剂治疗患有获得性甲状腺功能减退症的青少年

• 批准号: 7374960
• 负责人: PARVIN YAZDANI-KACHOOEI
• 金额: $ 0.53万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7374960
• 关键词: GROWTH; HORMONE; GNRH; AGONIST; ADOLESCENTS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Growth failure is a significant manifestation of acquired prolonged hypothyroidism, resulting in permanent loss in height and only seventy percent catch-up growth is achieved with thyroxine replacement. Patients treated with thyroxine at a mean chronologic age of 11 years have adult heights approximatley two standard deviations below the mean-final hights and are lower than the mid-parental and predicted adult heights. The concomitant administration of growth hormone to restore growth rate, in addition to a Gonadrotrophin releaseing (GNRHa) to arrest epiphysial maturation, offers the possibility of improving final height prognosis. This randomized study will evaluate the long-term effect of concomitant administration of growth hormone and GNRHa in addition to thyroxine vs. standard therapy of thyroxine alone on th efinal height of adolescents with prolonged juvenile hypothyroidism. In addition, a cohort of patients with short duration of hypothyroidism will also be followed to delineate the effects of short vs. prolonged hypothyroidism on growth.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。生长衰竭是获得性延长甲状腺功能减退症的显着表现，导致身高永久损失，甲状腺素替补仅实现了70％的追赶增长。用甲状腺素治疗的患者在平均年龄为11年的年龄为11年的成人身高大约是平均最终的高标准偏差，低于育儿和预测的成人高度。除了促性腺营养蛋白释放（GNRHA）外，生长激素伴随生长激素恢复生长速率，以阻止表面性成熟，还提供了改善最终高度预后的可能性。这项随机研究还将评估除甲状腺素与单独甲状腺素对甲状腺素的标准治疗外，生长激素和GNRHA的长期影响对长期少年甲状腺功能减退症的青少年高度的高度。此外，还将遵循一系列短甲状腺功能减退症患者的队列，以描绘出短时间与长时间甲状腺功能减退症对生长的影响。